DE69133228D1 - Dna-expressionssysteme basierend auf alphaviren - Google Patents

Dna-expressionssysteme basierend auf alphaviren

Info

Publication number
DE69133228D1
DE69133228D1 DE69133228T DE69133228T DE69133228D1 DE 69133228 D1 DE69133228 D1 DE 69133228D1 DE 69133228 T DE69133228 T DE 69133228T DE 69133228 T DE69133228 T DE 69133228T DE 69133228 D1 DE69133228 D1 DE 69133228D1
Authority
DE
Germany
Prior art keywords
alphavirus
expression systems
systems based
dna expression
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69133228T
Other languages
English (en)
Other versions
DE69133228T2 (de
Inventor
Henrik Garoff
Peter Liljestroem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioption AB
Original Assignee
Bioption AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20381182&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69133228(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioption AB filed Critical Bioption AB
Publication of DE69133228D1 publication Critical patent/DE69133228D1/de
Application granted granted Critical
Publication of DE69133228T2 publication Critical patent/DE69133228T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
DE69133228T 1990-12-13 1991-12-12 Dna-expressionssysteme basierend auf alphaviren Expired - Fee Related DE69133228T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9003978A SE9003978D0 (sv) 1990-12-13 1990-12-13 Dna expressionssystem baserade paa ett virus replikon
PCT/SE1991/000855 WO1992010578A1 (en) 1990-12-13 1991-12-12 Dna expression systems based on alphaviruses

Publications (2)

Publication Number Publication Date
DE69133228D1 true DE69133228D1 (de) 2003-05-08
DE69133228T2 DE69133228T2 (de) 2003-10-30

Family

ID=20381182

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69133228T Expired - Fee Related DE69133228T2 (de) 1990-12-13 1991-12-12 Dna-expressionssysteme basierend auf alphaviren

Country Status (12)

Country Link
US (3) US5739026A (de)
EP (1) EP0561890B1 (de)
JP (2) JP3435511B2 (de)
AT (1) ATE236261T1 (de)
AU (1) AU656545B2 (de)
CA (2) CA2614365A1 (de)
DE (1) DE69133228T2 (de)
DK (1) DK0561890T3 (de)
ES (1) ES2195998T3 (de)
FI (1) FI932678A (de)
SE (1) SE9003978D0 (de)
WO (1) WO1992010578A1 (de)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770283B1 (en) * 1990-12-13 2004-08-03 Bioption Ab DNA expression systems based on alphaviruses
CA2523216C (en) * 1993-09-15 2010-11-16 Chiron Corporation Recombinant alphavirus vectors
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
SE9401091D0 (sv) 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
SE9401709D0 (sv) * 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5505947A (en) * 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
DE19512142A1 (de) * 1995-03-31 1996-10-02 Immuno Ag Infektiöser cDNA-Klon des Tick-Borne Enzephalitis (TBE)-Virus, davon abgeleiteter rekombinanter Impfstoff und Herstellung desselben sowie ein pharmazeutisches Produkt, das eine replizierbare Nukleinsäure enthält
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5639650A (en) * 1995-05-23 1997-06-17 The University Of North Carolina At Chapel Hill cDNA clone for South African Arbovirus No. 86
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6458560B1 (en) 1996-04-05 2002-10-01 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US5677124A (en) * 1996-07-03 1997-10-14 Ambion, Inc. Ribonuclease resistant viral RNA standards
US5939262A (en) * 1996-07-03 1999-08-17 Ambion, Inc. Ribonuclease resistant RNA preparation and utilization
US6489167B1 (en) 1996-09-25 2002-12-03 The Government Of The United States As Represented By The Secretary Of The Department Of Human Services Retroviral packaging cassettes amplified in the cytoplasm by autocatalytic Togavirus vectors
AU729690B2 (en) * 1996-10-10 2001-02-08 Henrik Garoff Alphavirus-retrovirus vectors
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6432699B1 (en) 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
CA2306443A1 (en) 1997-10-14 1999-04-22 Darwin Molecular Corporation Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
BR9813930A (pt) 1997-11-06 2006-12-19 Chiron Spa antìgeno neisserial
US6475780B1 (en) 1997-11-14 2002-11-05 Aventis Pasteur Limited Alphavirus vectors for paramyxovirus vaccines
EP1047784B2 (de) 1998-01-14 2015-03-18 Novartis Vaccines and Diagnostics S.r.l. Antigene aus neisseria meningitidis
JP2002510647A (ja) 1998-04-08 2002-04-09 ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 癌の治療のための方法および修飾細胞
US6844188B1 (en) 1998-04-08 2005-01-18 University Of North Carolina At Chapel Hill Methods and modified cells for the treatment of cancer
NZ532665A (en) 1998-05-01 2005-11-25 Inst Genomic Research Neisseria meningitidis antigens and compositions
JP4323720B2 (ja) * 1998-05-08 2009-09-02 インターベツト・インターナシヨナル・ベー・ベー 魚膵臓病ウイルス構造タンパク質およびその使用
WO2000022130A2 (en) 1998-10-15 2000-04-20 Chiron Corporation Metastatic breast and colon cancer regulated genes
NZ512456A (en) * 1998-11-30 2003-10-31 Cytos Biotechnology Ag Ordered molecular presentation of antigens
DE69939599D1 (de) 1998-12-16 2008-10-30 Novartis Vaccines & Diagnostic MENSCHLICHE CYCLIN-ABHÄNGIGE KINASE (hPNQALRE)
US8647864B2 (en) * 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
DK1175497T3 (da) 1999-04-14 2010-05-31 Novartis Vaccines & Diagnostic Præparater og fremgangsmåder til generering af et immunrespons ved udnyttelse af alfavirusbaserede vektorsystemer
NZ571167A (en) 1999-04-30 2010-05-28 Novartis Vaccines & Diagnostic Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
US6297013B1 (en) 1999-06-24 2001-10-02 Dnab Diagnostics Inc. Compositions and methods for determining the activity of DNA-binding proteins and of initiation of transcription
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
CA2721011A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
MXPA02004148A (es) 1999-10-26 2003-08-20 Int Aids Vaccine Initiative Vectores bacterianos invasivos para expresar replicones de alfavirus.
EP2975127A1 (de) 1999-10-29 2016-01-20 GlaxoSmithKline Biologicals SA Neisseria antigenpeptide
JP2003516731A (ja) 1999-11-18 2003-05-20 カイロン コーポレイション ヒトｆｇｆ−２１遺伝子および遺伝子発現産物
EP2275129A3 (de) 2000-01-17 2013-11-06 Novartis Vaccines and Diagnostics S.r.l. Ergänzter Außenmembranvesikel-Impfstoff gegen Meningokokken
WO2001066595A2 (en) 2000-03-08 2001-09-13 Chiron Corporation Human fgf-23 gene and gene expression products
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
CA2408328C (en) * 2000-05-10 2012-04-17 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
ES2312447T3 (es) * 2000-05-31 2009-03-01 Novartis Vaccines And Diagnostics, Inc. Procedimiento para la purificacion de particulas de replicon alfavirus.
US6783939B2 (en) 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
US6982087B2 (en) 2000-09-07 2006-01-03 The University Of North Carolina At Chapel Hill Vectors derived from South African Arbovirus No. 86
SG165981A1 (en) 2000-10-27 2010-11-29 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
AU2002227153B2 (en) 2000-12-08 2008-01-24 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US7128911B2 (en) * 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) * 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
JP5089847B2 (ja) * 2001-03-27 2012-12-05 ニューヨーク・ユニバーシティ アルファウイルスに基づく高親和性ラミニン受容体標的化ベクターを用いた腫瘍の治療
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
WO2002081639A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
WO2002081641A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
ES2340532T3 (es) 2001-06-05 2010-06-04 Curevac Gmbh Arnm con un contenido g/c aumentado que codifica para un antigeno bacteriano y utilizacion del mismo.
ATE437222T1 (de) 2001-09-06 2009-08-15 Alphavax Inc Alphavirus replikon-vektorsysteme
US7115266B2 (en) * 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
MXPA04002644A (es) 2001-10-05 2004-07-08 Cytos Biotechnology Ag Conjugados que portan un peptido de angiotensina y usos de los mismos.
EP2335723A1 (de) 2001-12-12 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Immunisierung gegen Chlamydia trachomatis
US7877273B2 (en) * 2002-01-08 2011-01-25 Fredric David Abramson System and method for evaluating and providing nutrigenomic data, information and advice
US20030219459A1 (en) * 2002-01-18 2003-11-27 Cytos Biotechnology Ag Prion protein carrier-conjugates
CN100593544C (zh) 2002-03-15 2010-03-10 惠氏控股有限公司 酶活性减少的非典型流感嗜血杆菌的p4蛋白突变体
AU2003223527B2 (en) 2002-04-09 2009-01-15 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
BR0311995A (pt) * 2002-06-20 2005-04-05 Cytos Biotechnology Ag Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso
EP2351770A1 (de) * 2002-07-17 2011-08-03 Cytos Biotechnology AG Molekulare Antigen-Anordnung durch Verwendung eines Virus ähnlichen Partikels vom Virus ap205
EP1523334A2 (de) * 2002-07-18 2005-04-20 Cytos Biotechnology AG Hapten-träger-konjugate und ihre verwendung
CA2492930C (en) 2002-07-19 2013-01-08 Cytos Biotechnology Ag Vaccine compositions containing amyloid beta1-6 antigen arrays
ATE465753T1 (de) 2002-10-21 2010-05-15 Eisai Inc Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
PT2279746E (pt) 2002-11-15 2013-12-09 Novartis Vaccines & Diagnostic Proteínas de superfície de neisseria meningitidis
ES2618309T3 (es) * 2002-12-13 2017-06-21 Alphavax, Inc. Partículas de replicón de alfavirus multi-antigénico y métodos
WO2004055167A2 (en) 2002-12-13 2004-07-01 Alphavax, Inc. Alphavirus particles and methods for preparation
EP1587908A4 (de) * 2003-01-09 2008-02-20 Invitrogen Corp Zelluläre zuführung und aktivierung von polypeptid-nukleinsäurekomplexen
KR101518309B1 (ko) * 2003-03-20 2015-05-08 알파벡스, 인크. 개선된 알파바이러스 레플리콘 및 헬퍼 구축물
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
WO2004102198A2 (en) * 2003-05-15 2004-11-25 Cytos Biotechnology Ag Selection of b cells with specificity of interest: method of preparation and use
DE602004021260D1 (de) * 2003-07-11 2009-07-09 Alphavax Inc Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
US7910093B2 (en) 2003-08-19 2011-03-22 New York University Method for detecting cancer cells and monitoring cancer therapy
KR101162970B1 (ko) * 2003-10-08 2012-07-12 테리온 바이오로직스, 인크. 변형된 ｃｅａ/ｂ7 벡터
JP2007518762A (ja) * 2004-01-20 2007-07-12 サイトス バイオテクノロジー アーゲー グレリン−担体結合体
CN104292321A (zh) 2004-03-29 2015-01-21 株式会社嘉尔药物 新的半乳凝素9 突变体蛋白质及其用途
MXPA06013124A (es) * 2004-05-18 2007-05-23 Alphavax Inc Vectores de alfavirus derivados de tc-83, particulas y metodos.
ES2292271B1 (es) * 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
CN1960752A (zh) * 2004-06-02 2007-05-09 赛托斯生物技术公司 非人类tnf－肽的载体偶联物的医药用途
US7189540B2 (en) * 2004-06-21 2007-03-13 Quattromed As Optimized recognition site of the alphavirus non-structural protease for tag removal and specific processing of recombinant proteins
WO2006085983A2 (en) 2004-07-09 2006-08-17 University Of North Carolina At Chapel Hill Viral adjuvants
US7998733B2 (en) 2004-10-05 2011-08-16 Merial Limited Chimeric vectors
CA2597921A1 (en) * 2005-02-15 2007-04-26 University Of North Carolina At Chapel Hill New live virus vaccines
SG10201912554TA (en) 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
US7303898B2 (en) * 2005-03-29 2007-12-04 New York University Defective sindbis viral vectors
ATE522541T1 (de) 2006-06-09 2011-09-15 Novartis Ag Bakterielle adhäsine konformere
CA2663298C (en) 2006-09-12 2015-11-24 Alphavax, Inc. Alphavirus replicon particles as immunological adjuvants
NZ575901A (en) 2006-09-12 2012-04-27 Alphavax Inc Alphavirus replicon particles matched to protein antigens as immunological adjuvants
AU2007317347B2 (en) * 2006-11-03 2014-02-06 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
WO2008116116A2 (en) 2007-03-20 2008-09-25 Harold Brem Gm-csf cosmeceutical compositions and methods of use thereof
CA2689588C (en) 2007-06-21 2016-08-23 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
PL2612868T3 (pl) 2007-11-01 2018-12-31 Astellas Pharma Inc. Immunosupresyjne polipeptydy i kwasy nukleinowe
ES2525707T3 (es) 2008-12-01 2014-12-29 Alphavax, Inc. Uso de microRNAs para el control de ácidos nucleicos colaboradores de virus
AU2010234362B2 (en) 2009-04-08 2015-11-26 Alphavax, Inc. Alphavirus replicon particles expressing TRP2
US8563261B2 (en) 2009-09-28 2013-10-22 The Trustees Of The University Of Pennsylvania Method of diagnosing and treating interstitial cystitis
EE05711B1 (et) 2009-10-07 2014-04-15 Tartu Ülikool Meetod ja kompositsioon konditsionaalselt letaalsete viirusmutantide loomiseks ja eukarootse raku elulisuse k?rvaldamiseks
WO2011064437A2 (es) 2009-11-26 2011-06-03 Proyecto De Biomedicina Cima, S.L. Vectores virales y procedimientos útiles en la preparación de gdnf
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US9198975B2 (en) 2010-12-01 2015-12-01 The University Of North Carolina At Chapel Hill Methods and compositions for targeting sites of neovascular growth
EP2668201A2 (de) 2011-01-28 2013-12-04 Sanofi Pasteur SA Immunologische zusammensetzungen mit hiv-gp41-polypeptidderivaten
SI2691530T1 (en) 2011-06-10 2018-08-31 Oregon Health & Science University CMV glycoproteins and recombinant vectors
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US20190282679A1 (en) * 2016-04-18 2019-09-19 Rima McLeod Toxoplasma gondii vaccines and their use
WO2018157141A1 (en) * 2017-02-27 2018-08-30 Translate Bio, Inc. Methods for purification of messenger rna
CN214973877U (zh) 2019-08-09 2021-12-03 胡桃钳医疗公司 用于形成治疗性多核苷酸的微流体设备及微流体路径装置

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1288073C (en) * 1985-03-07 1991-08-27 Paul G. Ahlquist Rna transformation vector
WO1989012095A1 (en) * 1988-06-10 1989-12-14 Applied Biotechnology, Inc. A method of evaluating recombinant vaccines against immunodeficiency virus
US4943628A (en) * 1988-06-13 1990-07-24 Ortho Pharmaceutical Corporation HIV peptide-inducted T cell stimulation
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems

Also Published As

Publication number Publication date
EP0561890B1 (de) 2003-04-02
DK0561890T3 (da) 2003-07-21
ATE236261T1 (de) 2003-04-15
JPH06504198A (ja) 1994-05-19
US20020151067A1 (en) 2002-10-17
CA2614365A1 (en) 1992-06-25
JP4018479B2 (ja) 2007-12-05
AU656545B2 (en) 1995-02-09
US6190666B1 (en) 2001-02-20
FI932678A (fi) 1993-07-27
DE69133228T2 (de) 2003-10-30
CA2098292A1 (en) 1992-06-14
AU9078791A (en) 1992-07-08
EP0561890A1 (de) 1993-09-29
ES2195998T3 (es) 2003-12-16
JP2003159085A (ja) 2003-06-03
WO1992010578A1 (en) 1992-06-25
US5739026A (en) 1998-04-14
JP3435511B2 (ja) 2003-08-11
SE9003978D0 (sv) 1990-12-13
FI932678A0 (fi) 1993-06-11

Similar Documents

Publication Publication Date Title
DE69133228D1 (de) Dna-expressionssysteme basierend auf alphaviren
BR7908410A (pt) Meio para deteccao de anticorpos de vhb no soro do sangue,e processo para deteccao da presenca da infeccao por virus da hepatite b em seres humanos
DE69131580T2 (de) GDF-1 und UOG1 Proteine
ES8500322A1 (es) Un metodo de modificar un virus para conferirle una nueva funcion biologica.
NO20013701D0 (no) HER-2/neu-fusjonsproteiner
ES2061708T3 (es) Virus recombinante de la viruela de la gallina, vectores de expresion de proteinas heterologas y vacunas para aves de corral derivadas de este virus.
UA42089C2 (uk) Протигрипозна вакцина на основі поверхневого антигену, спосіб її виробництва
DK0941318T5 (da) Håndvægtformede konstruerede ekspressionssystemer til genterapi
DK0757717T3 (da) Papillomavirusvacciner
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
MY102472A (en) Preparation of funtional human urokinase proteins.
DK251890D0 (da) Polypeptid og dets anvendelse samt ekspressionssystem til dets eksprimering
SE8105516L (sv) Syntetisk dna och forfarande for framstellning derav
AU590861B2 (en) New human lymphotoxin (TNF-beta) polypeptides their prepartion and use
DE69529750D1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
FI950516A (fi) Interferoni-alfa/beta-sitojaproteiini, sen valmistus ja käyttö
BR0010222A (pt) Vetores de expressão viral
DK0691404T3 (da) Vaccine til immunisering mod TBE-virusinfektioner samt en fremgangsmåde til fremstilling deraf
ATE320266T1 (de) Induktion von antigen-spezifischen t-zellen durch interferon
BR9915970A (pt) Vìrus recombinante expressando dna exógenocodificando cd80 felino, ctla-4 felino ou cd86 felinoe usos do mesmo
KR830010193A (ko) 바실러스 클로닝 매개체, 재결합 dna분자 그것들과 함께 변형된 간균 숙주 그리고 이종(異知) dna배열의 표현 방법과 그것으로 이루어진 폴리펩타이드의 생성방법
ATE102252T1 (de) Rekombinantes gefluegelpockenvirus, expressionsvektoren fuer heterologische proteine und davon derivierte gefluegelvakzine.
ATE93893T1 (de) Expressionssysteme zur ueberproduktion gewuenschter proteine.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8339 Ceased/non-payment of the annual fee